Pharmanutra Balance Sheet Health

Financial Health criteria checks 5/6

Pharmanutra has a total shareholder equity of €58.9M and total debt of €23.3M, which brings its debt-to-equity ratio to 39.6%. Its total assets and total liabilities are €115.6M and €56.7M respectively. Pharmanutra's EBIT is €26.4M making its interest coverage ratio 40.7. It has cash and short-term investments of €24.4M.

Key information

39.6%

Debt to equity ratio

€23.32m

Debt

Interest coverage ratio40.7x
Cash€24.40m
Equity€58.90m
Total liabilities€56.70m
Total assets€115.60m

Recent financial health updates

Recent updates

Investors Interested In Pharmanutra S.p.A.'s (BIT:PHN) Earnings

Sep 11
Investors Interested In Pharmanutra S.p.A.'s (BIT:PHN) Earnings

Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft Earnings

Mar 23
Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft Earnings

Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?

Sep 26
Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?

These 4 Measures Indicate That Pharmanutra (BIT:PHN) Is Using Debt Safely

May 16
These 4 Measures Indicate That Pharmanutra (BIT:PHN) Is Using Debt Safely

Pharmanutra (BIT:PHN) Could Easily Take On More Debt

Jan 11
Pharmanutra (BIT:PHN) Could Easily Take On More Debt

Capital Allocation Trends At Pharmanutra (BIT:PHN) Aren't Ideal

Nov 02
Capital Allocation Trends At Pharmanutra (BIT:PHN) Aren't Ideal

Pharmanutra (BIT:PHN) Will Be Hoping To Turn Its Returns On Capital Around

Aug 03
Pharmanutra (BIT:PHN) Will Be Hoping To Turn Its Returns On Capital Around

Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?

May 20
Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?

Returns On Capital Signal Tricky Times Ahead For Pharmanutra (BIT:PHN)

Apr 19
Returns On Capital Signal Tricky Times Ahead For Pharmanutra (BIT:PHN)

Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmanutra S.p.A.'s BIT:PHN) Stock?

Mar 10
Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmanutra S.p.A.'s BIT:PHN) Stock?

Is There More To The Story Than Pharmanutra's (BIT:PHN) Earnings Growth?

Feb 17
Is There More To The Story Than Pharmanutra's (BIT:PHN) Earnings Growth?

Should You Be Adding Pharmanutra (BIT:PHN) To Your Watchlist Today?

Feb 01
Should You Be Adding Pharmanutra (BIT:PHN) To Your Watchlist Today?

Is Pharmanutra S.p.A. (BIT:PHN) A Smart Choice For Dividend Investors?

Jan 18
Is Pharmanutra S.p.A. (BIT:PHN) A Smart Choice For Dividend Investors?

Is Pharmanutra (BIT:PHN) A Risky Investment?

Jan 04
Is Pharmanutra (BIT:PHN) A Risky Investment?

Shareholders Of Pharmanutra (BIT:PHN) Must Be Happy With Their 220% Total Return

Dec 22
Shareholders Of Pharmanutra (BIT:PHN) Must Be Happy With Their 220% Total Return

Do Insiders Own Lots Of Shares In Pharmanutra S.p.A. (BIT:PHN)?

Dec 08
Do Insiders Own Lots Of Shares In Pharmanutra S.p.A. (BIT:PHN)?

Is Pharmanutra S.p.A.'s(BIT:PHN) Recent Stock Performance Tethered To Its Strong Fundamentals?

Nov 23
Is Pharmanutra S.p.A.'s(BIT:PHN) Recent Stock Performance Tethered To Its Strong Fundamentals?

Financial Position Analysis

Short Term Liabilities: PHN's short term assets (€63.4M) exceed its short term liabilities (€28.1M).

Long Term Liabilities: PHN's short term assets (€63.4M) exceed its long term liabilities (€28.6M).


Debt to Equity History and Analysis

Debt Level: PHN has more cash than its total debt.

Reducing Debt: PHN's debt to equity ratio has increased from 19.2% to 39.6% over the past 5 years.

Debt Coverage: PHN's debt is well covered by operating cash flow (98.1%).

Interest Coverage: PHN's interest payments on its debt are well covered by EBIT (40.7x coverage).


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 03:35
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pharmanutra S.p.A. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrea RandoneIntermonte SIM S.p.A.
Giorgio TavoliniIntermonte SIM S.p.A.
Daniele AlibrandiStifel, Equities Research